# Characterizing early symptomatic AD patients by visual and quantitative tau profiles

## TL;DR

This study examines different tau profiles in early Alzheimer's patients to understand how they progress clinically and biologically.

## Contribution

The study identifies distinct tau profiles (V++/Q- and V+/Q+) in early symptomatic Alzheimer's patients and compares their progression patterns.

## Key findings

- The V++/Q- and V+/Q+ groups showed less clinical progression compared to the V++/Q+ group.
- Age-related comorbidities may explain milder AD pathology in the V++/Q- and V+/Q+ groups.
- Biomarker progression was similar across all groups despite differing clinical outcomes.

## Abstract

In the TRAILBLAZER‐ALZ 2 study (NCT04437511), tau pathology at screening was evaluated with flortaucipir Positron Emission Tomography (PET) with a combination of visual read (V) and quantitative (Q) standardized uptake value ratio (SUVr) approaches. In most cases, participants had an advanced Alzheimer's disease (AD) tau visual pattern (AD++) with an AD‐signature weighted neocortical SUVr>1.1 (V++/Q+). A minority of participants presented other V/Q profiles, namely an AD++ visual read with an SUVr≤1.1 (V++/Q‐) and a moderate AD tau pattern (AD+) with an SUVr>1.1 (V+/Q+). The objective of these analyses was to characterise these populations.

All available TRAILBLAZER‐ALZ 2 placebo‐treated early symptomatic AD participants were included. Baseline characteristics and progression on both clinical scales (Clinical Dementia Rating ‐ Sum of Boxes [CDR‐SB], integrated Alzheimer Disease Rating Scale [iADRS]) and biomarkers (p‐tau217, glial fibrillary acidic protein [GFAP], neurofilament light chain [NfL]) at Week 76 (using mixed model repeated measures methodology), of the V++/Q‐ and V+/Q+ groups were compared to each other and to the rest of the study population (V++/Q+).

The V++/Q‐ group comprised 15.7% (126/802) and the V+/Q+ group 2.9% (23/802) of the placebo‐treated study population with characteristics as shown in the Table. At Week 76, all groups were at risk of clinical progression, although changes from baseline in CDR‐SB and iADRS for the V++/Q‐ and V+/Q+ groups were less compared to the rest of the population (significantly different between the V++/Q‐ and V++/Q+ groups; p <0.0001 for both CDR‐SB and iADRS) (Figure). Progression for both AD‐specific and non‐AD specific biomarker progression was similar across all groups.

The observation of V++/Q‐ and V+/Q+ participants being older, milder in AD pathology while at a similar clinical stage at screening compared to V++/Q+ participants may suggest the effect of age‐related comorbidities. Participants in the V++/Q‐ and the V+/Q+ groups showed clinical/pathological progression, although not at the level of those in the V++/Q+ group.